About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our main scientific interest is to understand, from a multidisciplinary and translational approach, the molecular and cellular processes leading to renal dysfunction in several kidney pathologies. Specifically, our research lines are
We are experts on the following areas:
To sum up, our research main objective is to combine –omic data from cellular and animal models with patients’ data to identify novel biomarkers and possible treatments for several renal diseases.
Our group is focused in research in primary or inherited tubular renal diseases, such as Dent’s Disease, Bartter syndrome, Tubular Acidosis, Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis, among others. Currently we are collaborating with other groups in Spain, within a research project named Renaltube the main purpose of which is to build a database while facilitating access to genotyping in order to improve the clinical and molecular knowledge of primary tubulopathies. Renaltube has a web-based approach with multilateral collaboration scheme that enhances the recruitment of data and promotes the understanding of underlying mechanisms of rare inherited diseases, defines more accurate diagnostic and follow-up criteria, develops new molecular techniques and will improve the overall care of the patients. Currently we are offering the analysis of 22 genes corresponding to 23 primary tubulopathies. After two years of activity Renaltube has collected data from 222 patients, the mayority from Spain and Latin America (85.3%). The most common tubulopathies are distal renal tubular acidosis (22.5%), and classical Bartter syndrome (19.3%) followed by familial hypomagesemia with hipercalciuria and nephrocalcinosis (15.7%), and Gitelman syndrome (15%).
IP: Gema Ariceta Iraola, Anna Meseguer Navarro
Overexpression of this protein in 60% of the ccRCCs has already been described. HAVR/KIM-1 overexpression in human ccRCC cell lines blocks cell differentiation and promotes cell scattering. We aim to determine the role of HAVR/KIM-1 in the development and progression of ccRCC, and its possible value as a diagnostic and prognostic biomarker. We also focus on KIM-1’s role in ischemia/reperfusion- or nephrotoxic-induced renal tubular injury. Overexpression of this protein in kidney injury has been described. However, whether its involvement is associated with processes enabling to recover tubular epithelium or potentially increasing damage is not known to this date. With the assistance of cultured renal tubular cell models, we are now investigating whether KIM-1 expression shifts are correlated with renal proximal tubule regeneration ability and, as a consequence, investigating its potential therapeutic application.
IP: Anna Meseguer Navarro
IP: Anna Meseguer Navarro Collaborators: Gerard Cantero Recasens, Miriam Izquierdo Sans Funding agency: Asociación Española Contra el Cáncer Funding: 150000 Reference: INVES234762CANT Duration: 15/11/2023 - 14/11/2026
IP: Gerard Cantero Recasens Collaborators: - Funding agency: Mizutani Foundation for Glycoscience Funding: 45000 Reference: MIZUTANI FOUNDATION FOR GLYCOSCIENCE - 2022 Duration: 01/04/2023 - 31/03/2024
IP: Anna Meseguer Navarro Collaborators: Gema Ariceta Iraola, Alejandro Cruz Gual, Gerard Cantero Recasens, David Lorente García, Marina Muñoz López, Mercedes López González, Hector Rios Duro, Mónica Durán Fernández, Luis Augusto Castro Sáder, Gloria Mª Fraga Rodriguez, Julieta Torchia Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 01600 Duration: 01/01/2022 - 30/06/2025
IP: Joan Morote Robles Collaborators: Fernando Lozano Palacio, Inés de Torres Ramirez, Marta Barber Servera, Enric Trilla Herrera, Olga Méndez Fernández, Ana Celma Domènech, Mercè Cuadras Solé, Carlos Serrano Burgos, Albert Carrión Puig , Maria Eugenia Semidey Raven, Carles Xavier Raventós Busquets, David Ruiz Casajuana, Jacques Planas Morin, Richard Mast, Anna Santamaria Margalef Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00858 Duration: 01/01/2022 - 30/06/2025
PMID: 37260991 Journal: Clinical Kidney Journal Year: 2023 Reference: Clin Kidney J. 2022 Nov 29;16(6):985-995. doi: 10.1093/ckj/sfac251. eCollection 2023 Jun. Impact factor: Publication type: Paper in international publication Authors: Adoracion Martin, Maria; Agraz-Pamplona, Irene; Blasco, Miquel; Bouarich, Hanane; Cabezas, Antonio; Canal, Cristina; Castro-Alonso, Cristina; Dall'Anese, Cecilia; Del Carmen Merino, Maria; Del Rio Garcia, Laura et al. DOI: 10.1093/ckj/sfac251
PMID: 37487638 Journal: Life Science Alliance Year: 2023 Reference: Life Sci Alliance. 2023 Jul 24;6(10):e202201886. doi: 10.26508/lsa.202201886. Print 2023 Oct. Impact factor: Publication type: Paper in international publication Authors: Barbas, Coral; Chaix, Amandine; Herrero, J Ignacio; Lamas, Santiago; Lin, Terry; Meseguer, Anna; Miguel, Veronica; Panda, Satchidananda; Ramos, Ricardo; Rey-Serra, Carlos et al. DOI: 10.26508/lsa.202201886
PMID: 37689688 Journal: World Journal of Emergency Surgery Year: 2023 Reference: World J Emerg Surg. 2023 Sep 9;18(1):45. doi: 10.1186/s13017-023-00513-8. Impact factor: Publication type: Review in international publication Authors: Abu-Zidan, Fikri M; Agnoletti, Vanni; Aisoni, Filippo; Ammendola, Michele; Ansaloni, Luca; Bala, Miklosh; Biffl, Walter; Catena, Fausto; Ceccarelli, Graziano; Ceresoli, Marco et al. DOI: 10.1186/s13017-023-00513-8
PMID: 37702442 Journal: NEW ENGLAND JOURNAL OF MEDICINE Year: 2023 Reference: N Engl J Med. 2023 Sep 14;389(11):987-997. doi: 10.1056/NEJMoa2300161. Epub 2023 Sep 12. Impact factor: Publication type: Paper in international publication Authors: Alberici, Irene; Alberici, Irene; Alpay, Harika; Anarat, Ali; Ariceta, Gema; Ariceta, Gema; Ariceta, Gema; Atmis, Bahriye; Barbi, Egidio; Baskin, Esra et al. DOI: 10.1056/NEJMoa2300161
PMID: 35131032 Journal: eLife Year: 2022 Reference: Elife. 2022 Feb 8;11. pii: 73926. doi: 10.7554/eLife.73926. Impact factor: 8.146 Publication type: Paper in international publication Authors: Lobo-Jarne, Teresa; Garrido, Marta; Iglesias, Mar; Espinosa, Lluis; Malhotra, Vivek; Alonso-Maranon, Josune; Cantero-Recasens, Gerard et al. DOI: 10.7554/eLife.73926
PMID: 35137195 Journal: NEPHROLOGY DIALYSIS TRANSPLANTATION Year: 2022 Reference: Nephrol Dial Transplant. 2022 Feb 7. pii: 6523371. doi: 10.1093/ndt/gfac029. Impact factor: 5.992 Publication type: Paper in international publication Authors: Decramer, Stephane; Devuyst, Olivier; van Dyck, Maria; Ferraro, Pietro Manuel; Fila, Marc; Francisco, Telma; Ghiggeri, Gian Marco; Gondra, Leire; Guarino, Stefano; Hooman, Nakysa et al. DOI: 10.1093/ndt/gfac029
PMID: 33779754 Journal: NEPHROLOGY DIALYSIS TRANSPLANTATION Year: 2022 Reference: Nephrol Dial Transplant. 2022 Jun 23;37(7):1270-1280. doi: 10.1093/ndt/gfab075. Impact factor: 5.992 Publication type: Paper in international publication Authors: Marco, Helena; Caravaca-Fontan, Fernando; Diaz-Encarnacion, Montserrat; Cabello, Virginia; Ariceta, Gema; Quintana, Luis F; Barros, Xoana; Rodriguez-Mendiola, Nuria; Mon, Carmen; Fraga, Gloria et al. DOI: 10.1093/ndt/gfab075
PMID: 34971403 Journal: PEDIATRIC NEPHROLOGY Year: 2022 Reference: Pediatr Nephrol. 2022 Aug;37(8):1867-1875. doi: 10.1007/s00467-021-05226-1. Epub 2021 Dec 31. Impact factor: 3.714 Publication type: Paper in international publication Authors: Jobs, K; Yazicioglu, Burcu; Bakkaloglu, Sevcan A; Abranches, M; Akman, S; Alpay, H; Ariceta, G; Atmis, B; Bael, A; Bakkaloglu, S A et al. DOI: 10.1007/s00467-021-05226-1
PMID: 33841866 Journal: Clinical Kidney Journal Year: 2021 Reference: Clin Kidney J. 2021 Mar 30;14(4):1207-1215. doi: 10.1093/ckj/sfaa247. eCollection 2021 Apr. Impact factor: 4.452 Publication type: Paper in international publication Authors: Jatem, Elias, Madrid, Alvaro, Lopez, Mercedes, Segarra, Alfons, Martinez, Cristina, Roca, Neus et al. DOI: 10.1093/ckj/sfaa247
PMID: 26538615 Journal: NEPHROLOGY DIALYSIS TRANSPLANTATION Year: 2016 Reference: Nephrol Dial Transplant. 2016 Mar;31(3):495-505. doi: 10.1093/ndt/gfv368. Epub 2015 Nov 3. Impact factor: 4.085 Publication type: Paper in international publication Authors: Ruiz, Juan C, Porrini, Esteban L, Diaz, Jose M, Moreso, Francisco, Delgado Mallen, Patricia I, Silva Torres, Irene, Ibernon, Meritxell, Bayes-Genis, Beatriz, Benitez-Ruiz, Rocio, Lampreabe, Ildefonso et al. DOI: 10.1093/ndt/gfv368
The research will perform a functional analysis of phenotype-modifying genetic variants in patients affected by familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (HFHNC).
The project, which has received funding from the Association for Genetic Kidney Disease Information and Research, aims to help develop new therapies for familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
The association supports the Kidney Pathophysiology group at VHIR since 2015 to investigate familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
